Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19

Study Overview
=================
Brief Summary
-----------------
A multicenter prospective cohort study performed at 6 major teaching hospitals in Southern Norway to study patient reported outcomes, lung function and pulmonary CT in patients at 3 and 12 months after hospitalization for coronavirus disease 2019 (COVID-19).

Detailed Description
-----------------
This cohort study aim to describe the Natural course of COVID-19 disease in an consecutive and unselected cohort of Norwegians that have been hospitalized. In addition to the primary and secondary outcomes related to PROMS, lung function and pulmonary CT, the study also have several substudies: Cardiology: The study includes echocardiography, 24-h electrocardiography and cardiopulmonary exercise test. ENT: The study includes CT of head sinuses and patient-reported sleep disturbances and nose symptoms in a subgroup of patients. Laboratory: Analyses of common markers of inflammation and cardiac biomarkers.

Official Title
-----------------
Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19

Conditions
-----------------
Covid19, Lung Function Decreased

Intervention / Treatment
-----------------
* Other: No interventions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Discharged before June 1 2020 after hospitalization at participating hospital for COVID-19 Exclusion Criteria: Age < 18 years Dementia Living outside hospital catchment area Participation in WHO COVID-19 clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No interventions|No interventions|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Forced vital capacity | L | 3 months | 
| Forced vital capacity | L | 12 months | 
| Gas diffusion capacity of carbon monoxide | mmol/kPa*min | 3 months | 
| Gas diffusion capacity of carbon monoxide | mmol/kPa*min | 12 months | 
| modified Medical Respiratory Council Dyspnea Scale | Unit | 6 weeks | 
| modified Medical Respiratory Council Dyspnea Scale | Unit | 3 months | 
| modified Medical Respiratory Council Dyspnea Scale | Unit | 12 months | 
| Parenchymal opacities of the lungs | Number of opacities in one lung zone | 3 months | 
| Parenchymal opacities of the lungs | Number of opacities in one lung zone | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Forced expiratory capacity during 1st second of expiration | L | 3 months | 
| Forced expiratory capacity during 1st second of expiration | L | 12 months | 
| FEV1/FVC | Percentage | 3 months | 
| FEV1/FVC | Percentage | 12 months | 
| Gas diffusion capacity adjusted for alveolar ventilation (KCO) | mmol/kPa*min*L | 3 months | 
| Gas diffusion capacity adjusted for alveolar ventilation (KCO) | mmol/kPa*min*L | 12 months |